CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that Claes Glassell,
president and chief executive officer, is scheduled to present a
corporate update at the Cowen and Company 30th Annual Health Care
Conference on Tuesday, March 9th at 4:30 pm ET. The conference will be
held at the Boston Marriott Copley Place.
A live webcast of the presentation will be available from the Investor
Relations page of the Cerus web site at http://cerus2013.q4web.com.
A replay will be available for approximately two weeks following the
completion of the event.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused on
commercializing the INTERCEPT Blood System to enhance blood safety. The
INTERCEPT system is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range of
pathogens such as viruses, bacteria and parasites that may be present in
donated blood. The nucleic acid targeting mechanism of action allows
INTERCEPT treatment to inactivate both established transfusion threats,
such as hepatitis, HIV, West Nile virus and bacteria, as well as
emerging pathogens such as influenza, malaria and dengue. Cerus
currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in Europe, Russia, the Middle East and selected
countries in other regions around the world. The INTERCEPT red blood
cell system is in clinical development. See http://www.cerus.com
for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
Source: Cerus Corporation